Kabra Drugs FY26 Results: Net profit turns positive at ₹496 lakh
- Net profit turned positive to ₹495.98 lakh in FY26 from a loss of ₹108.56 lakh in FY25
- Revenue from operations jumped to ₹9,274.00 lakh after resuming trading operations
- Operating cash flow remained negative at ₹(946.09) lakh due to rising receivables
- Trade receivables surged to ₹7,077.60 lakh, while cash reserves fell to ₹1,058.23 lakh
- Company renamed Aanjaay Industries Limited and shifted registered office to Chennai

*this image is generated using AI for illustrative purposes only.
Aanjaay Industries Limited (formerly Kabra Drugs Limited) returned to profitability in FY26, reporting a net profit of ₹495.98 lakh against a net loss of ₹108.56 lakh in FY25. The turnaround was driven by the resumption of commercial activities, which generated revenue from operations of ₹9,274.00 lakh, compared to nil in the preceding year.
The company’s total expenses stood at ₹8,751.20 lakh, dominated by purchases of stock-in-trade amounting to ₹8,366.40 lakh. This cost structure yielded a gross margin of approximately 9.8%. Other income contributed ₹49.27 lakh to the bottom line, primarily from interest income, while tax expenses were recorded at ₹76.09 lakh.
What the Numbers Show
Despite the accounting profit, the company’s operating cash flow was negative at ₹(946.09) lakh. This divergence stems from a significant increase in trade receivables, which rose to ₹7,077.60 lakh from ₹60.05 lakh in the prior year. While trade payables also increased substantially to ₹5,487.98 lakh, the net working capital requirement absorbed cash generated from operations. Cash and cash equivalents declined to ₹1,058.23 lakh from ₹2,129.93 lakh.
Balance Sheet Position
Total assets expanded to ₹8,631.56 lakh from ₹2,522.90 lakh in FY25. Current assets accounted for ₹8,396.84 lakh, largely driven by the receivable buildup. On the liability side, current liabilities rose to ₹5,658.48 lakh, with trade payables constituting the majority. The company maintained a debt-equity ratio of 0.01, with borrowings limited to ₹42.91 lakh, mostly from directors.
Corporate Developments
The company changed its name to Aanjaay Industries Limited effective July 6, 2026, and shifted its registered office to Chennai. The Board appointed Ms. Moonam Kapoor as an independent director and Mrs. Twinkle Agarwal as secretarial auditor for a five-year term. The 37th Annual General Meeting is scheduled for September 30, 2026.
Historical Stock Returns for Kabra Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.52% | +5.40% | -14.14% | -31.62% | +13.84% | 0.0% |
How does the company plan to address the significant divergence between accounting profit and negative operating cash flow caused by the sharp rise in trade receivables?
What specific strategies will Aanjaay Industries implement to improve its thin 9.8% gross margin and reduce dependency on high stock-in-trade costs?
Given the substantial increase in current liabilities, what is the management's outlook on debt servicing and liquidity management for the upcoming fiscal year?


































